News
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
EQS-News: Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
EQS-News: Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinic
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Amarin Plc (NASDAQ: AMRN)Q4 2023 Earnings CallFeb 29, 2024, 8:00 a.m. ET
Operator
Source Fool.com
EQS-News: Gerresheimer decisively continues on profitable growth course in financial year 2023
Henry Ford Health and Acadia Healthcare Appoint Emily Sexton as CEO of New Henry Ford Behavioral Health Hospital
Henry Ford Health, one of the nation’s premier academic and integrated health systems, and Acadia Healthcare, the nation’s largest stand-alone behavioral healthcare company, today announced the
2 Stocks Under $30 to Buy and Hold
What is a reasonable sum of money to start investing in stocks? $10,000? $1,000? $500? The truth is, thanks to online brokers who now offer trades at low or no fees and fractional shares, investors
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its full-year 2023 financial results.
This press release features multimedia. View the full release
EQS-News: Sartorius releases Annual Report for 2023
Orlando Health and Acadia Healthcare Hold Groundbreaking Ceremony for New Behavioral Health Hospital to Serve Greater Orlando Area
Orlando Health and Acadia Healthcare today held a ceremony to celebrate the start of construction on a previously announced 144-bed behavioral health hospital that will expand access to critical
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
Danish pharmaceutical company Novo Nordisk (NYSE: NVO) just made the headlines for something other than Ozempic. Well, sort of. One of the company's subsidiaries, Novo Holdings, is responsible for
EQS-News: The Supervisory Board of Sartorius AG proposes a dividend of 0.74 euros per preference share
EQS-News: Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q4 2023 Earnings CallFeb 06, 2024, 5:00 p.m. ET
Operator
Source Fool.com
EQS-Adhoc: SARTORIUS AG: Sartorius successfully completes placement of 200 million euros of treasury preference shares
EQS-Adhoc: SARTORIUS AG: Sartorius launches placement of up to 200 million euros of treasury preference shares through accelerated bookbuilding
Why Catalent Stock Soared Today
Shares of Catalent (NYSE: CTLT) rose by 9.7% on Monday after the pharmaceutical contract manufacturing and drug delivery technology specialist agreed to be acquired by Novo Holdings, the parent
Why Novo Nordisk Stock Crushed the Market on Monday
A major acquisition by its controlling shareholder pushed Novo Nordisk's (NYSE: NVO) U.S.-listed shares 4% higher on Monday. As a result of the deal, Novo Nordisk will acquire from that shareholder
EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
EQS-News: MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
Is Invitae Stock a Buy Now?
Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to
EQS-News: Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028